Cargando…
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/ https://www.ncbi.nlm.nih.gov/pubmed/35214799 http://dx.doi.org/10.3390/vaccines10020341 |
_version_ | 1784658033853333504 |
---|---|
author | Achtnichts, Lutz Ovchinnikov, Arkady Jakopp, Barbara Oberle, Michael Nedeltchev, Krassen Fux, Christoph Andreas Sellner, Johann Findling, Oliver |
author_facet | Achtnichts, Lutz Ovchinnikov, Arkady Jakopp, Barbara Oberle, Michael Nedeltchev, Krassen Fux, Christoph Andreas Sellner, Johann Findling, Oliver |
author_sort | Achtnichts, Lutz |
collection | PubMed |
description | Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme. |
format | Online Article Text |
id | pubmed-8875864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88758642022-02-26 SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot Achtnichts, Lutz Ovchinnikov, Arkady Jakopp, Barbara Oberle, Michael Nedeltchev, Krassen Fux, Christoph Andreas Sellner, Johann Findling, Oliver Vaccines (Basel) Article Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme. MDPI 2022-02-21 /pmc/articles/PMC8875864/ /pubmed/35214799 http://dx.doi.org/10.3390/vaccines10020341 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Achtnichts, Lutz Ovchinnikov, Arkady Jakopp, Barbara Oberle, Michael Nedeltchev, Krassen Fux, Christoph Andreas Sellner, Johann Findling, Oliver SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title | SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title_full | SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title_fullStr | SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title_full_unstemmed | SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title_short | SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot |
title_sort | sars-cov-2 mrna vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/ https://www.ncbi.nlm.nih.gov/pubmed/35214799 http://dx.doi.org/10.3390/vaccines10020341 |
work_keys_str_mv | AT achtnichtslutz sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT ovchinnikovarkady sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT jakoppbarbara sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT oberlemichael sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT nedeltchevkrassen sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT fuxchristophandreas sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT sellnerjohann sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot AT findlingoliver sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot |